Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer

American Journal of Health-System Pharmacy

Volumn 62, Issue 13, 2005, Pages 1365-1369

  Wilhelm, Lindsey ^a   Kolesar, Jill M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Antineoplastic agents; Carcinoma; Combined therapy; Costs; Economics; Resistance; Surgery; Tegafur; Uracil

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ETOPOSIDE; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; NITROSOUREA; PACLITAXEL; PEMETREXED; PLATINUM; PODOPHYLLOTOXIN DERIVATIVE; TAXANE DERIVATIVE; TENIPOSIDE; TOPOTECAN; UFT; VINBLASTINE; VINCA ALKALOID; VINDESINE;

BONE MARROW APLASIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; FEBRILE NEUTROPENIA; HEALTH CARE COST; HUMAN; HYPONATREMIA; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TINNITUS;

EID: 22144440896     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040529     Document Type: Review

References (11)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55:10-30.
2. National Comprehensive Cancer Network. Non-small cell lung cancer. Clinical practice guidelines in oncology v2. 2005. www.nccn.org/professionals/ physician_gls/PDF/nscl.pdf (accessed 2005 Mar 29).
3. Lynch TJ Jr. Lung cancer highlights. Oncologist. 2000; 5:274-9.
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311:899-909.
5. Spiro SG, Rudd RM, Souhami RL et al. Chemotherapy vs supportive care in advanced nonsmall cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004; 59:828-36.
6. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350:351-60.
7. Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer. J Natl Cancer Inst. 2003; 95:1453-61.
8. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350: 1713-21.
9. Hotta K, Matsuo K, Ueoka H et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol. 2004; 22:3860-7.
10. Winton TL, Livingston R, Johnson D et al., for the National Cancer Institute of Canada Clinical Trials Group. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) intergroup JBR. J Clin Oncol. 2004; 22:A7018. Abstract.
11. Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol. 2004; 22:A7019. Abstract.